DrugPatentWatch

DrugPatentWatch is a biopharmaceutical intelligence platform that aggregates patent, pipeline, litigation, pricing, and market data from primary sources across 134 countries, updated daily. It is designed for pharmaceutical professionals — including generic manufacturers, biotech firms, healthcare procurement teams, and business development leads — who need timely, primary-source data to inform decisions around generic entry, patent risk, litigation strategy, and market opportunity.

The platform draws directly from sources such as the USPTO, FDA Orange Book, ANDA filings, litigation records, and national patent registers worldwide. Data is refreshed continuously, and users can export full datasets in structured formats that remain in their possession permanently, independent of subscription status.

Core Platform Capabilities

• Patent Litigation Intelligence: Provides access to full complaints and court documents. Users can review failed patent challenges to inform litigation strategy and anticipate early generic entry timelines.
• Generic Entry Opportunities: Identifies drugs with expiring or expired patents to support portfolio decisions, due diligence, and tracking of investigational compounds at various development stages.
• Global Drug Patents: Covers branded and generic market opportunities across 134 countries, including identification of markets where competitors hold weak or absent patent protection.
• Market Entry Strategy: Provides historic sales figures to assess market potential, evaluate buyer power, and align distribution approaches with reimbursement segmentation data.
• AI Research Assistant: A Deep Research Engine that returns answers drawn from multiple data sources, with full citations provided for verification.
• Automated Reports and Dashboards: Supports automated monitoring workflows, custom alert configuration, and scheduled delivery of intelligence updates.

Data Access and Query Features

• All drug profiles are updated from primary sources on a daily basis, with no editorial lag or publication cycle delays.
• Users can run their own queries against raw data rather than inheriting a pre-defined analytical framework.
• Full datasets can be downloaded in clean, structured formats; exported data is retained by the user permanently.
• The platform allows users to revisit and modify queries as strategic needs change, without requiring a new engagement or additional cost.

Patent Expiry Tracking

• The platform tracks patent expiry timelines for specific drugs, with examples including pembrolizumab (Keytruda, 2028), apixaban (Eliquis, 2026), adalimumab (Humira, expired), and semaglutide (Ozempic, 2032).
• Expiry data is drawn from primary regulatory and patent sources and updated continuously to reflect the current state of each drug's patent status.

Pricing and Cost Context

• DrugPatentWatch is offered on monthly subscription plans, positioned as a lower-cost alternative to boutique pharma intelligence engagements, which the platform notes typically range from $20,000 to $100,000 or more per engagement.
• A free trial is available, with tiered plans offered to accommodate different organisational scales.

The platform is used by organisations in over 70 countries, including generic pharmaceutical companies, healthcare systems, biotech firms, and LATAM distributors. It has been cited by outlets including CNN, the New England Journal of Medicine, Nature, Reuters, and Bloomberg, and has been in operation for over 20 years.